Asset Details
Do you wish to reserve the book?
Current treatment landscape for relapsed and/or refractory multiple myeloma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Current treatment landscape for relapsed and/or refractory multiple myeloma
Do you wish to request the book?
Current treatment landscape for relapsed and/or refractory multiple myeloma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Current treatment landscape for relapsed and/or refractory multiple myeloma
2015
Overview
Key Points
There is currently no uniform standard of care for the treatment of patients with relapsed and/or refractory multiple myeloma (MM), but combination regimens are generally preferred over monotherapy
Incorporation of immunomodulatory drugs and proteasome inhibitors into anti-MM treatment regimens has improved survival rates in these difficult-to-treat patients
Each anti-MM agent is associated with a distinct safety profile that can impact treatment selection and its use in combination with other agents
An understanding of disease-related and patient-related factors, as well as treatment-related toxicities, is critical for evaluating appropriate therapeutic options for each patient
Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients. Currently, there is no standard treatment for patients with relapsed and/or refractory disease. This Review discusses the current treatment landscape for patients with relapsed and/or refractory multiple myeloma and highlights disease-related and patient-related factors that are important considerations for clinicians when selecting an appropriate treatment.
Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients. Recurrence of myeloma is typically more aggressive with each relapse, leading to the development of treatment-refractory disease, which is associated with a shorter survival. Several phase II and III trials have demonstrated the efficacy of recently approved agents in the setting of relapsed and/or refractory multiple myeloma, including immunomodulatory agents, such as lenalidomide and pomalidomide, and proteasome inhibitors, such as bortezomib and carfilzomib. Currently, however, there is no standard treatment for patients with relapsed and/or refractory disease. This Review discusses the current treatment landscape for patients with relapsed and/or refractory multiple myeloma and highlights disease-related and patient-related factors—such as pre-existing comorbidities or toxicities—that are important considerations for clinicians when selecting an appropriate treatment regimen.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Analysis
/ Angiogenesis Inhibitors - therapeutic use
/ Antineoplastic Agents - therapeutic use
/ Boronic Acids - therapeutic use
/ Hematopoietic Stem Cell Transplantation
/ Humans
/ Medicine
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - mortality
/ Multiple Myeloma - pathology
/ Neoplasm Recurrence, Local - drug therapy
/ Oligopeptides - therapeutic use
/ Oncology
/ Peripheral Nervous System Diseases - complications
/ Thalidomide - analogs & derivatives
